HEALTHSTAT NEWS
Opinion: Limb girdle muscular dystrophy patients face a maddening reality
The author shares their experience of being diagnosed with limb girdle muscular dystrophy (LGMD) and highlights the lack of available treatments or cures. They emphasize the urgency for faster drug development due to the irreversible muscle loss caused by delays. The article notes advancements in gene therapies and FDA opportunities to modernize rare disease treatments.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Next-gen Duchenne drug from Entrada disappoints
- Opinion: Ten years after WHO recognition, mycetoma remains one of the world’s most neglected diseases
- STAT+: Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submission
- Closing the Gap Between Innovation and Access in Myasthenia Gravis Care [Promoted Content]
- NHS drugs go-ahead offers lifeline to children with rare muscle-wasting disease